Date: 2015-06-19
Type of information: Restructuring
Compound:
Company: Incyte (USA - DE)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: restructuring
Action mechanism:
Disease:
Details: * On June 19, 2015, Incyte announced that it has created two new units to better position the organization for future growth in the U.S. and internationally. One of these is a U.S. country organization that will lead commercial and medical affairs in the United States . In the future, the company expects to establish other similar country- or regionally-based organizations. The other new unit is a Global Product Strategy and Business Development & Licensing (BD&L) unit that will lead global competitive strategies for Incyte\'s expanding portfolio beyond Jakafi® (ruxolitinib), as well as review business development opportunities.
Financial terms:
Latest news:
